Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa.
A 34-year-old white man developed acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. If interferon alfa is to be used as a therapeutic option for scleromyxedema the possibility of rhabdomyolysis should be considered. To the best of our knowledge, this is the first case in which acute rhabdomyolysis was developed during the treatment of scleromyxedema with interferon alfa.